The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
NOTICE OF EXTRAORDINARY GENERAL MEETING IN INTERVACC AB (PUBL)
The shareholders of Intervacc AB (publ), reg. no. 556238-1748 (the “Company”), are hereby invited to the Extraordinary General Meeting (“EGM”) to be held on Friday 5 May 2023 at 10.00 a.m. at Good Morning Hotel, Västertorpsvägen 131, in Hägersten. The Board of...The Board of Directors in Intervacc intends to resolve on a fully covered rights issue of approximately SEK 100 million
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER...Intervacc publishes the 2022 Annual Report
Stockholm, April 6, 2023 – Intervacc AB (publ) announces that the company’s 2022 Annual Report has been published today. The annual report (in Swedish) is attached and an English unaudited translation of the report is available for download on the...Year-end report January – December 2022
The period in summary January 1 – December 31, 2022 In the end of March the first batch of Strangvac® was released for sale in Sweden, and in the end of May we passed another milestone in the fight against strangles when Strangvac® was released for sale in...Intervacc’s Chief Scientific Officer Dr Andrew Waller presents at the FEEVA European Horse Welfare Symposium in Amsterdam
Stockholm, January 24, 2023 – Intervacc’s Chief Scientific Officer Dr Andrew Waller will talk about the prevention of equine strangles at the Federation of European Equine Veterinary Associations (FEEVA) European Horse Welfare Symposium 2023 on the 28th of...Nyhetstjänster
